14 November 2024 - Knight Therapeutics announced today that Health Canada has approved Jornay PM, an extended-release formulation of methylphenidate, a stimulant medication for the treatment of attention deficit hyperactivity disorder in children.

Jornay PM is the first and only evening dosed methylphenidate product commercially available in Canada to treat attention deficit hyperactivity disorder in patients from 6 to 12 years of age.

Read Knight Therapeutics press release